A phase I trial of90Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 2, 2006, Pages 88-100

  Wong, Jeffrey Y C ^a   Chu, David Z ^a   Williams, Lawrence E ^a   Liu, An ^a   Zhan, Jiping ^a   Yamauchi, Dave M ^a   Wilczynski, Sharon ^a   Wu, Anna M ^a,b   Yazaki, Paul J ^a   Shively, John E ^a   Leong, Lucille ^a   Raubitschek, Andrew A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

90yttrium; Carcinoembryonic antigen; DOTA; Phase I; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; ANTIBODY CONJUGATE; CARCINOEMBRYONIC ANTIGEN; PENTETATE CALCIUM; PENTETATE INDIUM IN 111; PENTETIC ACID; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ANEMIA; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG ABSORPTION; DRUG UPTAKE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOGENICITY; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; URINALYSIS;

EID: 33744816826     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.88     Document Type: Article

References (59)

1. 131I anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459.
2. DeNardo GL, Lewis JP, DeNardo SJ, et al. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 1994;73:1425.
3. I31I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995;85:1122.
4. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995;55:5899S.
5. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219.
6. Gordon LI, Witzig TE, Wiseman GA, et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Sem Oncol 2002;29:87.
7. Zelenetz AD. A clinical and scientific overview of tositumomab and iodine I-131 tositumomab. Sem Oncol (Suppl) 2003;30:22.
8. Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994;35:1017.
9. Juweid ME, Sharkey RM, Behr T, et al. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2. J Nucl Med 1996;37:1504.
10. DeNardo SJ, O'Grady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res 1997;17:1745.
11. 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J Nucl Med 2000;41:1168.
12. Breitz HB, Weiden PL, Vanderheyden J-L, et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy results of phase I trials. J Nucl Med 1992;33:1099.
13. 186Re-labeled bivatuzumab in patients with head and neck cancer. J Nucl Med 2003;44:1690.
14. Wong JYC, Shibata S, Williams LE, et al. A phase I trial of Y-90-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 2003;9:5842.
15. De Nardo SJ, Kramer EL, O'Donnell RT, et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: Results of a phase I clinical trial. J Nucl Med 1997;38:1180.
16. DeNardo SJ, O'Grady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res 1997;17:1745.
17. Breitz HB, Weiden PL, Vanderheyden JL, et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med 1992;33:1099.
18. Postema EJ, Borjesson PK, Buijs WC, et al. Radioimmunotherapy of head and neck cancer with 186-re-labeled humanized moncolonal antibody bivatuzumab. A dosimetric analysis. [abstract] J Nucl Med 2002;43:158P.
19. DeNardo SJ, Kramer EL, O'Donnell RT, et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: Results of a phase I clinical trial. J Nucl Med 1997;38:1180.
20. Wong JYC, Chu DZ, Yamauchi DM, et al. Phase I radioimmunotherapy trials evaluating Y-90-labeled anti-CEA chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 2000;6:3855.
21. 131I-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994;12:1561.
22. Divgi CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 1995;36:586.
23. Stewart JS, Hird V, Snook D, et al. Intraperitoneal radioimmunotherapy for ovarian cancer: Pharmacokinetics, toxicity, and efficacy of 1-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 1989;16:405.
24. Jacobs AJ, Fer M, Su FM, et al. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response. Obstet Gynecol 1993;82:586.
25. Deshpande SV, DeNardo SJ, Kukis DL, et al. Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990;31:473.
26. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm 2001;16:305.
27. 90yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 2002;8:2806.
28. Richman CM, DeNardo SJ, O'Donnell RT, et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium 111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res 2005;11:5920.
29. Meares CF, Moi MK, Diril H, et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer 1990;10:21.
30. DeNardo SJ, Zhong GR, Salako Q, et al. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice. J Nucl Med 1995;36:829.
31. Harrison A, Walker CA, Parker D, et al. The in vivo release of Y90 from cyclic and acyclic ligand-antibody conjugates. Int J Radiat Appl Instrum Part B, Nucl Med Biol 1991;18:469.
32. Griffiths GL, Govindan SV, Sharkey RM, et al. 90Y-DOTA-hLL2: An agent for radioimmunotherapy of non-Hodgkins' lymphoma. J Nucl Med 2003;44:77.
33. Camera L, Kinuya S, Garmestani K, et al. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetra- azacyclododecane tetra-acetic acid (2B-DOTA). Eur J Nucl Med 1994;21:640.
34. DeNardo GL, Kroger LA, DeNardo SJ, et al. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer 1994;73:1012.
35. 131I. J Nucl Med 2001;42:967.
36. 177Lu) in advanced prostate cancer (Pea). [abstract] Am Soc Clin Oncol 2002;21:5A.
37. 177Lu)-labeled CC49 monoclonal antibody (MAb) in patients with advanced adenocarcinoma. (meeting abstract) Proc Annu Meet Am Soc Clin Oncol 1993;12:A956.
38. 90Y-DOTATOC. J Nucl Med 2005;46:1310.
39. 177LU-DOTA-Y3-octreotate in a rat model. Int J Cancer 2001;94:873.
40. 1-octreotate: A somatostatin analog for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconjug Chem 2002;13:721.
41. 90yttrium radiolabeled anti-CEA chimeric T84.66 in a phase I radioimmunotherapy trial. Cancer Res 1995;55:5929S.
42. 90Y)-chimeric T84.66 (cT84.66) anti-CEA antibody and autologous stem cell support in CEA-producing metastatic breast cancer. Proc Am Assoc Cancer Res 1998;39:380.
43. Hefta LJ, Wu AM, Neaumaier M, et al. Measuring antibody affinity using biosensors. In: Chiswell D, Mac-Cafferty J, Moogenboom H, eds. Antibody Engineering: A Practical Approach. London: Oxford Press, 1996:99.
44. Neumaier M, Shively L, Chen FS, et al. Cloning of the genes for T84.66, an antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells. Cancer Res 1990;50:2128.
45. Wong JY, Thomas GE, Yamauchi D, et al. Clinical evaluation of indium-111 -labeled chimeric anti-CEA monoclonal antibody. J Nucl Med 1997;38:1951.
46. Lewis MR, Kao JY, Anderson A-L, et al. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjug Chem 2001;12:320.
47. Wong JY, Chu DZ, Yamauchi D, et al. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients. J Nucl Med 1998;39:2097.
48. Odom-Maryon TL, Williams LE, Chai A, et al. Pharmacokinetics modeling and absorbed dose estimation for a chimeric anti-CEA antibody (cT84.66) in humans. J Nucl Med 1997;38:1959.
49. Loevinger R, Berman M. MIRD Pamphlet No.1. A schema for absorbed-dose calculations for biologically distributed radionuclides. J Nucl Med 1968;9(Suppl 1):7.
50. Stabin MG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538.
51. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm 1990;3:213.
52. Thomas SR, Maxon HR, Kereiakes JG. In vivo queantitation of lesion radioactivity using external counting methods. Med Physics 1976;3:253.
53. Loevinger R, Japha EM, Brownell GL. In: Radiation Dosimetry. New York: Academic Press, 1956.
54. Loevinger R, Holt JG, Hine GJ. In: Radiation Dosimetry. New York: Academic Press, 1956.
55. Lewis MR, Raubitschek A, Shively JE. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjug Chem 1994;5:565.
56. 90Y-labeled monoclonal antibody in erythroleukemic mice. Cancer Res 1987;47:1905.
57. Wong JYC, Wang J, Liu A, et al. Evalauting changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy. Int J Radiat Oncol Biol Phys 2000;3:599.
58. Kosmas C, Snook D, Gooden CS, et al. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res 1992;52:904.
59. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994;15:42.